List outflow: 112 drugs are under special monitoring 44 traditional Chinese medicine preparations

▍ it is reported that the list of key monitoring drugs has been released again Recently, in order to maintain the safety of medical insurance fund, prevent excessive medical treatment, effectively improve the level of rational use of drugs, control the unreasonable growth of medical expenses, and improve the efficiency of the use of basic medical insurance fund, Weihai Medical Security Bureau held a medical expert seminar on key monitoring drugs of Weihai medical insurance At the meeting, the clinical use of drugs found in the early monitoring of drug use in hospitals at all levels in the city was reported, and the related drugs were analyzed and discussed The experts at the meeting unanimously discussed and agreed that the first batch of 27 drugs, such as monosialotetrahexosylganglioside and oxiracetam, will be under key monitoring, forming the first batch of key monitoring drugs catalogue in Weihai City At the same time, the experts at the meeting discussed and formulated the second batch of 85 kinds of drug catalogue monitored according to the situation ▍ 112 drugs are listed, and 44 traditional Chinese medicine preparations cover 112 drugs in total according to the opinion of medical insurance expert group on catalogue of key monitoring drugs (auxiliary drugs) in Weihai City circulated in the industry There are 27 drugs listed in the first batch of key monitoring drugs in Weihai City Compared with the first batch of key monitoring drugs list for rational use (chemical and biological products) published by the national health and Health Commission, there are 8 kinds of drugs that overlap They are ganglioside, oxiracetam, alprostadil, troxerutin Cerebroprotein hydrolysate, Danshen Ligustrazine, thymopentin, vinpocetine, etc The second batch of key controlled drugs in Weihai City has 85 varieties, including 41 injections and 44 traditional Chinese medicine preparations The injections include meropenem, vancomycin, Yanhuning, guipaizite, aescin, levocarnitine, Ozagrel, troxerutin, rat nerve growth factor, brain glycoside and carnosine, calf blood deproteinized extract, etc Traditional Chinese medicine preparations include Reduning injection, Tanreqing injection, Shenfu injection, Chuankezhi injection, Huangqi injection, Shengmai injection, Shenmai injection, Yiqi Fumai injection (freeze-dried), Xiangdan injection, Danshen injection, Danshen injection, Mailuoning injection, safflower yellow sodium chloride injection, Kudiezi Injection, Ginkgo biloba injection, Notoginseng Injection Saponin injection preparation, Guanxinning Injection, Shuxuetong injection, Zhengqingfengtongning injection, Shenkang injection, Xiaozhiling injection, Cinobufacin injection, Aidi injection, xiaocaiping injection, Brucea javanica oil emulsion injection, Shenqi Fuzheng injection, Kangai injection, ginkgolide injection, astragalus polysaccharide for injection, safflower injection, guaweipi injection, Deng Zhan injection preparation, Shuganning injection, Breviscapine injection preparation, safflor yellow for injection, Guhong injection, Breviscapine injection, etc It can be seen that almost all of the 26 restricted Chinese patent medicines in the 2017 version of the medical insurance catalogue are in the list of drugs under the key monitoring of Weihai medical insurance bureau It is reported that in the next step, Weihai medical insurance bureau will adjust the catalogue from time to time, establish a monitoring and early warning system for key monitoring drugs, report the information of designated medical institutions and medical insurance doctors whose use of key monitoring drugs exceeds the monitoring indicators every quarter, and deal with the designated medical institutions and responsible medical insurance doctors who violate the regulations ▍ the health and medical insurance departments strictly control the auxiliary drugs According to the notice of "the first batch of national key monitoring list of rational drugs (chemical drugs and biological products)" issued by the Health Administration Bureau of the national health and Health Commission, the provincial health administration departments, together with the Chinese Medicine Department in charge, shall form and publish the provincial key monitoring list of rational drugs on the basis of the list All kinds of medical institutions at all levels shall, on the basis of provincial catalogues, form their own catalogues of key monitoring drugs for rational use, and at the same time, the catalogues of key monitoring drugs at all levels shall be publicized to the public It is not hard to see that the national health and Health Commission clearly requires the health and health administrative departments at all levels to publish the list of key monitoring drugs However, up to now, according to the incomplete statistics of saibelan, the local institutions that have published the list of key monitoring drugs include Xingan League Medical Insurance Bureau of Inner Mongolia Autonomous Region and Weihai medical insurance bureau According to the requirements of the national health and Health Commission, all medical institutions should establish a management system focusing on monitoring the rational use of drugs, and strengthen the whole process management of the clinical application of drugs in the catalogue In order to ensure rational drug use, measures such as ranking notification, rectification within a time limit and clearing out the drug supply catalogue of the agency shall be taken for the varieties with prominent unreasonable drug use problems At the same time, the notice requires the prescription management of drugs out of the catalog It is not difficult to see that the health and health department issues the key monitoring drug catalog for the purpose of ensuring the rational use of drugs The motivation of the health insurance department to issue the catalogue of key monitoring (auxiliary drugs) is more direct - to control the unreasonable growth of medical expenses and ensure the safety of the use of health insurance funds Take Sanming, Fujian, the star of medical reform, as an example The local medical insurance department has always been the main body to control the auxiliary drugs Fujian Medical Insurance Bureau has also issued a notice on the key monitoring drugs, which directly points out that for the drugs with large dosage, high amount, and repeatedly failing to drop, they can be punished with the suspension of use It is not hard to see that for the management of key monitoring drugs (auxiliary drugs), the health department and the medical insurance department have their own demands, and the key monitoring drugs face multiple management pressures However, from the two policy objectives of rational drug use and medical insurance fee control, the relevant pharmaceutical enterprises can still actively act to strengthen the policy adaptability of varieties.